Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is InterMedical Care and Lab Hospital PCL Debt-to-EBITDA?
InterMedical Care and Lab Hospital PCLBKK:IMH +10.53%62 Debt-to-EBITDA is 4.14 as of Mar. 2026, which is 172% above its 10-year median of 1.52. GuruFocus rates BKK:IMH with a GF Score™ of 62/100 and a GF Value™ of ฿4.44 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 478 Healthcare Providers & Services companies, InterMedical Care and Lab Hospital PCL ranks worse than 209204.81% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BKK:IMH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -23.62 Med: 1.52 Max: 79.98
Current: -23.62
During the past 10 years, the highest Debt-to-EBITDA Ratio of InterMedical Care and Lab Hospital PCL was 79.98. The lowest was -23.62. And the median was 1.52.
BKK:IMH's Debt-to-EBITDA is ranked worse than 100% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.195
vs BKK:IMH: -23.62
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
InterMedical Care and Lab Hospital PCL Debt-to-EBITDA Related Terms
InterMedical Care and Lab Hospital PCL Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InterMedical Care and Lab Hospital PCL Debt-to-EBITDA Chart
InterMedical Care and Lab Hospital PCL Annual Data
BKK:IMH vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, InterMedical Care and Lab Hospital PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InterMedical Care and Lab Hospital PCL Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, InterMedical Care and Lab Hospital PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where InterMedical Care and Lab Hospital PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
InterMedical Care and Lab Hospital PCL (BKK:IMH) has a Debt-to-EBITDA of 4.14 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on InterMedical Care and Lab Hospital PCL. This is 172% above median its historical median of 1.52. According to the industry distribution chart, InterMedical Care and Lab Hospital PCL ranks #999999 out of 478 companies in the Healthcare Providers & Services industry.
Is InterMedical Care and Lab Hospital PCL's Debt-to-EBITDA too high?
InterMedical Care and Lab Hospital PCL's current Debt-to-EBITDA of 4.14 is 172% above median its 10-year median of 1.52. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.20. InterMedical Care and Lab Hospital PCL's value of 4.14 is 88.6% above this industry median. Based on the distribution chart, InterMedical Care and Lab Hospital PCL ranks #999999 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, InterMedical Care and Lab Hospital PCL has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does InterMedical Care and Lab Hospital PCL's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, InterMedical Care and Lab Hospital PCL ranks #999999 out of 478 companies for Debt-to-EBITDA. This places InterMedical Care and Lab Hospital PCL in the lower half of its industry. The industry median Debt-to-EBITDA is 2.20. InterMedical Care and Lab Hospital PCL's value of 4.14 is 88.6% above this benchmark. While the company's 10-year median is 1.52 vs. the industry median of 2.20, InterMedical Care and Lab Hospital PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.20, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InterMedical Care and Lab Hospital PCL's current Debt-to-EBITDA of 4.14 is 88.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on InterMedical Care and Lab Hospital PCL. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InterMedical Care and Lab Hospital PCL's current Debt-to-EBITDA is 4.14, which is 172% above median its own 10-year median of 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InterMedical Care and Lab Hospital PCL stock overvalued right now?
Based on GuruFocus' analysis, InterMedical Care and Lab Hospital PCL (BKK:IMH) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿4.44, compared to a current price of ฿3.78 — trading 14.9% below its estimated fair value. The current Debt-to-EBITDA is 4.14, which is 172% above median its 10-year median of 1.52 and 88.6% above the Healthcare Providers & Services industry median of 2.20. InterMedical Care and Lab Hospital PCL's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For InterMedical Care and Lab Hospital PCL (BKK:IMH), the current Debt-to-EBITDA is 4.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InterMedical Care and Lab Hospital PCL (BKK:IMH) Overvalued in 2026?
Based on GuruFocus' analysis, InterMedical Care and Lab Hospital PCL stock appears to be undervalued.
The current stock price of ฿3.78 is trading 14.9% below its estimated GF Value™ of ฿4.44.
GuruFocus considers InterMedical Care and Lab Hospital PCL to be Modestly Undervalued.
Key valuation signals for BKK:IMH:
Debt-to-EBITDA: 4.14 (172% above median its 10-year median of 1.52)
GF Value™: ฿4.44 vs. price of ฿3.78 (14.9% below fair value)
Industry Position: 88.6% above the Healthcare Providers & Services median (#999999 of 478)
No single metric tells the full story. See the BKK:IMH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InterMedical Care and Lab Hospital PCL is a company principally engaged in specialty medical hospitals, and occupational medicine. The business segments of the firm are Prachapat hospital, Occupational Medicine hospital and Environmental Analysis. Prachapat Hospital is engaged in rendering medical services to patients under government welfare schemes. Occupational Medicine Hospital is engaged in providing physical examination services. Majority of revenue is from Hospital Segment. Geographically, the company operates in Thailand.
62GF Score
Get the complete analysis for BKK:IMH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:IMH has been successfully added to your 
